Compare · NVST vs WST
NVST vs WST
Side-by-side comparison of Envista Holdings Corporation (NVST) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVST and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.22B, about 5.9x NVST ($3.76B).
- Over the past year, NVST is up 21.5% and WST is up 40.5% - WST leads by 18.9 points.
- NVST has been more active in the news (12 items in the past 4 weeks vs 4 for WST).
- NVST has more recent analyst coverage (23 ratings vs 16 for WST).
- Company
- Envista Holdings Corporation
- West Pharmaceutical Services Inc.
- Price
- $23.11+1.07%
- $314.41-0.90%
- Market cap
- $3.76B
- $22.22B
- 1M return
- -14.60%
- +0.26%
- 1Y return
- +21.54%
- +40.47%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2019
- News (4w)
- 12
- 4
- Recent ratings
- 23
- 16
Envista Holdings Corporation
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands. This segment also offers software packages used for the treatment planning of dental implants and prosthetics. The company's Equipment & Consumables segment develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; handpieces and associated consumables; treatment units and other dental practice equipment; endodontic systems and related consumables; and restorative materials and instruments, rotary burs, impression materials, bonding agents and cements, and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, KaVo, Kerr, Metrex, Sybron Endo, Total Care, and Pentron brands to dental offices, clinics, and hospitals. The company was incorporated in 2018 and is headquartered in Brea, California.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest NVST
- Envista Holdings Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form SD filed by Envista Holdings Corporation
- Chief Executive Officer Keel Paul A covered exercise/tax liability with 12,811 shares, decreasing direct ownership by 3% to 371,574 units (SEC Form 4) to satisfy tax liability
- Henry Schein Announces the Election of William K. "Dan" Daniel as Independent Chairman of the Board
- Director Tsingos Christine A was granted 9,330 shares, increasing direct ownership by 18% to 59,930 units (SEC Form 4)
- Director Carruthers Wendy was granted 9,330 shares, increasing direct ownership by 18% to 59,940 units (SEC Form 4)
- Director Raskas Daniel was granted 9,330 shares, increasing direct ownership by 21% to 54,010 units (SEC Form 4)
- Director Huennekens R Scott was granted 12,585 shares, increasing direct ownership by 18% to 82,105 units (SEC Form 4)
- Director Pierce James Andrew was granted 9,330 shares, increasing direct ownership by 102% to 18,485 units (SEC Form 4)
- Director Gallahue Kieran was granted 9,330 shares, increasing direct ownership by 21% to 54,010 units (SEC Form 4)
Latest WST
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)